Research Article Open Access

The Construction of Two and Three Dimensional Molecular Models for the miR-31 and Its Silencer as the Triple Negative Breast Cancer Biomarkers

Arli Aditya Parikesit1
  • 1 Department of Bioinformatics, School of Life Sciences, Indonesia International Institute for Life Sciences, Jakarta, Indonesia

Abstract

The Triple Negative Breast Cancer (TNBC) is considered as the most difficult Breast Cancer type to be medicated. So far, the acceptable medication and diagnostics measure are based upon the proteomics-world view, especially with utilizing the natural products and their derivatives as drug candidates. However, as the transcriptomics-studies are getting more advanced, the research on non-coding (nc)RNA is being considered as a more feasible approach to deal with the TNBC. The miR-31, as the ncRNA that play part in the molecular mechanism of the TNBC, is extensively studied mainly for providing the biomarker and drug candidate. However, the molecular interaction and structures are mainly unknown and it is subject of investigation of this research. This research is utilizing the interplay of pipelines that consist of the Vienna RNA package for 2D RNA structure prediction and the simRNA/modeRNA packages for 3D RNA structure prediction. The result is a blueprint that satifactionary illustrates the RNA structure in a fine-grained manner. The miR-31 and its respective silencing (si)RNA are indeed could be useful to be biomarkers and blue-print for the drug design of the TNBC.

OnLine Journal of Biological Sciences
Volume 18 No. 4, 2018, 424-431

DOI: https://doi.org/10.3844/ojbsci.2018.424.431

Submitted On: 14 June 2018 Published On: 18 October 2018

How to Cite: Parikesit, A. A. (2018). The Construction of Two and Three Dimensional Molecular Models for the miR-31 and Its Silencer as the Triple Negative Breast Cancer Biomarkers. OnLine Journal of Biological Sciences, 18(4), 424-431. https://doi.org/10.3844/ojbsci.2018.424.431

  • 4,427 Views
  • 1,777 Downloads
  • 0 Citations

Download

Keywords

  • TNBC
  • ncRNA
  • miR-31
  • Transcriptomics
  • Drug Design